The Role of Metronomic Chemotherapy in the Era of Cancer Immunotherapy: An Oncologist’s Perspective
Hong Kong Special Administrative Region Cancer Centre, Hong Kong SAR, China
Curr. Oncol. 2019, 26(4), 422-424; https://doi.org/10.3747/co.26.4853
Submission received: 3 May 2019
/
Revised: 11 June 2019
/
Accepted: 9 July 2019
/
Published: 1 August 2019
Excerpt
Note: In lieu of an abstract, this is an excerpt from the first page.
Metronomic chemotherapy (MCTX) encompasses a set of chemotherapy (CTX) doses significantly below the conventional maximum tolerated dose (MTD) and delivered largely continually (without the prolonged drug-free breaks typical of MTD CTX). [...]
Share and Cite
MDPI and ACS Style
Tsao, S.Y. The Role of Metronomic Chemotherapy in the Era of Cancer Immunotherapy: An Oncologist’s Perspective. Curr. Oncol. 2019, 26, 422-424. https://doi.org/10.3747/co.26.4853
AMA Style
Tsao SY. The Role of Metronomic Chemotherapy in the Era of Cancer Immunotherapy: An Oncologist’s Perspective. Current Oncology. 2019; 26(4):422-424. https://doi.org/10.3747/co.26.4853
Chicago/Turabian StyleTsao, S.Y. 2019. "The Role of Metronomic Chemotherapy in the Era of Cancer Immunotherapy: An Oncologist’s Perspective" Current Oncology 26, no. 4: 422-424. https://doi.org/10.3747/co.26.4853
